| Detailed information |
|---|
| CancerLivER ID | 2501 |
| Biomarker | NMNAT3, OASL, TMPRSS3, MFSD7, AEBP1, UBD, S100A4, C1orf151, CRIP1, ASCC3, ZNF271, ANXA4, NMI, UBE2L6, B2 M, HLA-F, PSMB9, TAP1, PSME2, IFI16, IFI27, ARHGAP9, RABGAP1L, TNK1, DEF6, BTN3A3, RPS6KA1, CD24, PARP10, APOL3, STAT, ANKRD10, CKB, H2AFZ, PSMB9, RARRES3, RGS10, TUBB, NOL3, CD7, |
| Biomarker Name/Symbol (given in Publication) | 40 genes-signature (NMNAT3, OASL, TMPRSS3, MFSD7, AEBP1, UBD, S100A4, C1orf151, CRIP1, ASCC3, ZNF271, ANXA4, NMI, UBE2L6, B2 M, HLA-F, PSMB9, TAP1, PSME2, IFI16, IFI27, ARHGAP9, RABGAP1L, TNK1, DEF6, BTN3A3, RPS6KA1, CD24, PARP10, APOL3, STAT, ANKRD10, CKB, H2AFZ, PSMB9, RARRES3, RGS10, TUBB, NOL3, CD7) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential biomarkers for diagnosis of HCV-related HCC; but not validated on independent dataset |
| Experimental Condition | HCV related non-HCC v/s normal control |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCV related non-HCC than normal control (With 3-fold change) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 19821982 |
| Type of Biomarker | Diagnostic |
| Pathway | Antigen Presentation, Protein Ubiquitination, Interferon signaling, IL-4 signaling, Bacteria and Viruses cell cycle and chemokine signaling pathways. |
| Cohort | 14 HCV-related HCC and non-HCC counterpart, as well as 7 HCV-negative control patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV-associated HCC |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |